Skip to main content Skip to navigation
Department of Chemistry Jones Research Group
NAME
Jones, Jeffrey, P.
POSITION TITLE
Professor of Chemistry
Don Matteson Professor of Chemistry
Ralph Yount Distinguished Professor of Chemistry
EDUCATION/TRAINING

INSTITUTION AND LOCATION

DEGREE

YEAR

FIELD OF STUDY

University of Michigan
Ann Arbor, MI

B.S.

1982

Medicinal Chemistry

University of Washington
Seattle, WA

Ph.D

1987

Medicinal Chemistry

University of Wisconsin
Madison, WI

Postdoctoral

1988-90

Biochemistry

Professional Experience

1987-88Postdoctoral Fellow in the laboratory of Professor William Trager, Department of Medicinal Chemistry, University of Washington, Seattle, WA
1988-89Postdoctoral Fellow in the laboratory of Professor W. W. Cleland, Department of Biochemistry, University of Wisconsin, Madison, WI
1990-95Assistant Professor, Department of Pharmacology, University of Rochester, Rochester, NY
1996-98Associate Professor, Department of Pharmacology and Physiology, University of Rochester, Rochester, NY
1996-98Associate Professor of Biophysics, University of Rochester, Rochester, NY
1998-02Associate Professor, Department of Chemistry, Washington State University, Pullman, WA
2002-PresProfessor, Department of Chemistry, Washington State University, Pullman, WA
2008-PresDon and Marianna Matteson Professor of Chemistry
2014-presRalph G. Yount Distinguished Professor of Chemistry

Other Experience

1998-2003  Member of the Scientific Advisory Board for Camitro Corporation
1998  Cofounder of Camitro Corporation with Ken Korzekwa and Camilla Olsen
2001  An expert panelist for the EPA QSAR workshop on risk assessment
2001-2002  President of the WSU Faculty Association for Scholarship and Research
2003-Present  Member of Drug Metabolism and Disposition Editorial Board
2004-2009  American Cancer Society Grant Reviewer
2007-2012  Grant Reviewer, Member, XNDA study section
2010  Grant reviewer for NCI, Special Emphasis Panels
2013  Co-Chair of the Platform Session for EB2013 in Boston, April 2013
2013  Chair of the Division for Drug Metabolism Executive Committee
2013-2014  Drug Metabolism Division Program Committee Liaison for EB2014
2015Grant reviewer NIH, Special Emphasis Panel, ZTR Developmental Pharmacology and Toxicology: Role of Ontogeny

Publications: (selected publications)

Korzekwa KR, Jones JP, and Gillette JR.  Theoretical studies on cytochrome P-450 mediated hydroxylation:  A predictive model for hydrogen atom abstractions.  J. Amer. Chem. Soc. 112:  7042-7046, 1990.

Jones JP, and Urbauer JL.  Theoretical kinetic isotope effects for hydride transfer from formate to carbon dioxide:  A comparison of theory with experiment.  J. Comp. Chem. 12:  1134-1141, 1991.

Jones JP, Trager WF, and Carlson TJ.  The binding and regioselectivity of reaction of (R) and (S)-nicotine with cytochrome P-450cam:  Parallel experimental and theoretical studies.  J. Amer. Chem. Soc. 115:  381-387, 1993.

Korzekwa KR, Jones JP.  Predicting the cytochrome P450 mediated metabolism of xenobiotics.  Pharmacogenetics 3:  1-18, 1993.

Dinnocenzo JP, Karki SB, and Jones JP.  Isotope effects for the cytochrome P-450 oxidation of substituted N,N-dimethyl anilines.  J. Amer. Chem. Soc. 115:  7111-7116, 1993.

Yin H, Bennett G, and Jones JP.  Mechanistic studies of UDP-glucuronosyltransferase.  Chemico-Biol. Interact. 90:  47-58, 1994.

Jones JP, Shou M, and Korzekwa KR.  Stereospecific activation of the procarcinogen benzo[a]pyrene to probe the active site of the cytochrome P450 superfamily.  Biochemistry, 34: 6956-6961,1995.

Dinnocenzo JP, Karki SB, Jones JP, and Korzekwa KR.  The mechanism of oxidative amine dealkylation by cytochrome P450:  Application of isotope effect profiles.  J. Am. Chem. Soc., 117: 3657-3664, 1995.

Yin H, Anders MW, and Jones JP.  Metabolism of 1,2-dichloro-1-fluoroethane and 1-fluoro-1,2,2-trichloroethane:  Electronic factors govern the regioselectivity of cytochrome P450-dependent oxidation.  Chem. Res. Toxicol. 9:  50-57, 1996.

Jones JP, He M, Trager WF, and Rettie AW.  3D-QSAR for inhibitors of cytochrome P450 2C9. Drug Metab. Dispos. 24:  1-6, 1996.

Jones JP, and Korzekwa KR.  Predicting binding affinities and rates of reaction for the P450 superfamily.  In:  “Methods in Enzymology.”  Ed. E. F. Johnson, and M. R. Waterman.  Invited Chapter, Vol. 272b, pp. 326-335, 1997.

Manchester JI, Dinnocenzo JP, Higgins L and Jones JP.  A new mechanistic probe for cytochrome P450.  J. Am. Chem. Soc. 119:  5069-5070, 1997.

Iyer KR, Jones JP, Darbyshire JF, and Trager WF.  Intramolecular isotope effects of benzylic hydroxylation of isomeric xylenes and 4,4’-dimethylbiphenyl by cytochrome P450:  Relationship between distance of methyl groups and masking of the intrinsic isotope effect.  Biochemistry 36:  7136-7143, 1997.

Higgins, L, Bennett, G. A., Shimoji, M. & Jones, J.P. Evaluation of Cytochrome P450 Mechanism and Kinetics Using Kinetic Deuterium Isotope Effects.  Biochemistry, 37, 7036-7046, 1998.

Shimoji, M., Yin, H., Higgins, L. Jones, J.P. Design of a Novel P450: A Functional Bacterial/Human Cytochrome P450 Chimera. Biochemistry, 37, 8848-8852, 1998.

Goto, Y., Watanabe, Y., Fukuzumi, S., Jones, J. P. Dinnocenzo, J. P. Mechanisms of N-Demethylations Catalyzed by High-Valent Species of Heme Enzymes: Novel Use of Isotope Effects and Direct Observation of Intermediates. J. Amer. Chem. Soc. 120: 10762-10763, 1998.

Audergon, C., Iyer, K.R., Jones, J.P., Darbyshire, J.F, Trager, W.F.  Experimental and theoretical approaches to study the active site topography of CYP101 (P450cam). J. Amer, Chem. Soc. 121, 41-47, 1999.

Haining, R.L., Jones, J.P., Henne, K., Fisher, M.B.,  Trager, W.F., Rettie, A.E. Phenylalanine 114 is a Critical, Substrate-Dependent Determinant of Specificity in Human Cytochrome P450 2C9.  Biochemistry, 38, 3285-3292, 1999.

Koenigs, L.L., Jones, J.P., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T.H., Trager, W. F. Mechanism-Based Inactivation of Cytochrome P450 3A4 by L-754,394.  Biochemistry, 2000;39:4276-87.

Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP, A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.J Med Chem. 2000;43:2789-96.

Higgins, L., Korzekwa, K.R., Shou, M., Jones, J.P. A Method for the Assessment of Reaction Energetics for Cytochrome P450 Mediated Reactions. Arch Biochem Biophys, 2001, 385, 220-230.

Ekins, S., de Groot, M.J., Jones, J.P. Pharmacophores and three Dimensional Quantitative Structure Activity Relationship Methods for Modeling Cytochrome P450 Active Sites. Drug Metab Dispos, 2001, 29, 936-944.

Rock D, Rock D, Jones JP.  Inexpensive purification of P450 reductase and other proteins using 2 ‘,5 ‘-adenosine diphosphate agarose affinity columns. Prot. Express. Pur. , 2001, 22: 82-83.

French, K. J., Strickler, M. D., Rock, D. A., Rock, D. A., Bennett, G. A., Wahlstrom, J. L. Goldstein, B. M., Jones, J. P.  Benign Synthesis of 2-ethylhexanoic acid by Cytochrome P450cam: Enzymatic, Crystallographic, and Theoretical Studies.  Biochemistry, 2001; 40; 9532-9538.

Kevin J. French, Dan A. Rock, Denise A. Rock, John I. Manchester, Barry M. Goldstein, and Jeffrey P. Jones* “Rational Design of Cytochrome P450cam: Understanding the structural basis for the oxidase shunt and improving the benign synthesis of 2-Ethylhexanoic Acid” Arch. Biochem. Biophys.2002, 398, 188-97.

Jeffrey P. Jones*, Michael Mysinger, Kenneth Ray Korzekwa “Computational Models for Cytochrome P450:  Predictive Electronic Model for Aromatic Oxidation and Hydrogen Atom abstraction” Drug Metab Disp.  2002, 1, 7-12.

Dan A. Rock, Anthony E. Boitano, Jan L. Wahlstrom, Denise A. Rock, and Jeffrey P. Jones* “The Use of Kinetic Isotope Effects to Delineate the Role of Phenylalanine 87 in P450BM-3 “  Bioorganic Chemistry, 2002; 30,  107-118.

Volz, T., Rock, D.A., Jones, J.P.“Direct Evidence for Two Different Active Oxygen Species in Cytochrome P450BM3 Mediated Sulfoxidation and N-Dealkylkation Reactions.” J Amer Chem Soc, 2002, 124(33); 9724-9725.

Strickler M, Goldstein BM, Maxfield K, Shireman L, Kim G, Matteson DS, Jones JP. “ Crystallographic studies on the complex behavior of nicotine binding to P450cam (CYP101).” Biochemistry. 2003 Oct 21;42(41):11943-50.

Rock DA, Perkins BNS, Wahlstrom J, Jones JP.  “A method for determining two substrates binding in the same active site of cytochrome P450(BM3): an explanation of high energy omega product formation.” Arch. Biochem. Biophysics. 416 (1): 9-16 AUG 1 2003.

Tornero-Velez R, Ross MK, Granville C, Laskey J, Jones JP, DeMarini DM,Evans MV “Metabolism and mutagenicity of source water contaminants 1,3-dichloropropane and 2,2-dichloropropane” Drug Metab Disp. 32 (1): 123-131 JAN 1 2004.

Dowers, T. S., Rock, D. A., Rock, D. A., Perkins, B. N. S., Jones, J. P. (2004).  “An analysis of the regioselectivity of aromatic hydroxylation and N-oxygenation by cytochrome P450 enzymes.” Drug Metab Disp. 32 (3): 328-332.

Dickmann, L. J., Locuson, C. W., Jones, J. P. and Rettie. A.E., “Differential Roles of Arg97, Asp293, and Arg108 in Enzyme Stability and Substrate Specificity of CYP2C9.” Mol Pharmacol 65: 842-850, 2004.

Locuson,C.W. II, Rock, D.A., and Jones, J.P., “Quantitative Binding Models for CYP2C9 Based on Benzbromarone Analogues, Biochemistry, Web Release Date: 13-May-2004.

Dowers, T. S., D. A. Rock, D. A. Rock and J. P. Jones (2004). “Kinetic isotope effects implicate the iron-oxene as the sole oxidant in P450-catalyzed N-dealkylation.” Journal of the American Chemical Society 126(29): 8868-8869.

Rettie, A., Jones, J.P. (2005) “Clinical and toxicological relevance of CYP2C9: Drug- drug interactions and pharmacogenetics” Annual Review of Pharmacology and Toxicology 45 477-494.

Hudelson MG, Jones JP. (2006) “Line-walking method for predicting the inhibition of p450 drug metabolism.” J Med Chem. 2006 Jul 13;49(14):4367-73.

Dowers TS, Jones JP (2006) “Kinetic isotope effects implicate a single oxidant for cytochrome P450-mediated O-dealkylation, N-oxygenation, and aromatic hydroxylation of 6-methoxyquinoline.” Drug Metab Dispos. 2006 Aug;34(8):1288-90.

Charles W. Locuson, Larry C. Wienkers, Jeffrey P. Jones, and Timothy S. Tracy (2007). “CYP2C9 Protein Interactions with Cytochrome b5: Effects on the Coupling of Catalysis.” Drug Metab Dispos., 35, 1174-1181.

Cho, K. Y., Y. Moreau, J.P. Jones and Shaik, S. (2007). “”Formation of the Active Species of Cytochrome P450 by Using Iodosylbenzene: A Case for Spin-Selective Reactivity”.” Chemistry: A European Journal 13: 4103-5115.

Sheridan, R.P., Korzekwa, K.R. , Rhonda A. Torres, R.A.,  Walker, M.  (2007). “Empirical Regioselectivity Models for Human Cytochromes P450 3A4, 2D6, and 2C9.” J Med Chem, 50, 3173-3184.

McMasters, D.R., Torres, R.A., Crathern, S.J., Dooney, D.L., Nachbar, R.B., Sheridan, R.P, Korzekwa, K.R. (2007). “Inhibition of Recombinant Cytochrome P450 Isoforms 2D6 and 2C9 by Diverse Drug-like Molecules” J Med Chem,  50, 3205-3213.

Torres, R.A., Korzekwa, K.R.,  McMasters, D.R., Fandozzi,I C.M.,  Jones, J.P. (2007). “On the Use of Density Functional Calculations to Predict the Regioselectivity of Drugs and Molecules Metabolized by Aldehyde Oxidase. J. Med. Chem, 50, 4642-4647.

Hudelson, M. G.; Ketkar, N. S.; Holder, L. B.; Carlson, T. J.; Peng, C.; Waldher, B. J.; Jones, J. P. (2008). “High Confidence Predictions of Drug−Drug Interactions: Predicting Affinities for Cytochrome P450 2C9 with Multiple Computational Methods.” J. Med. Chem.; 2008 Feb 14;51(3):648-54. Epub 2008 Jan 19.  DOI: 10.1021/jm701130z

Peng, C. C.,  Rushmore, T., Crouch, G. J., Jones, J. P. (2008). ” Modeling and Synthesis of Novel Tight-Binding Inhibitors of Cytochrome P450 2C9. Bioorganic and Medicinal Chemistry,” 2008 Apr 1;16(7):4064-74. Epub 2008 Jan18.

Peng, C. C., Rushmore, T., Crouch, G. J., Jones, J. P. (2008). “Cytochrome P450 2C9 Type II Binding Studies on Quinoline-4-Carboxamide Analogues” J. Med. Chem, 51 (24): 8000-8011.

Alfaro, J. F., Jones, J. P. (2008). ”Studies on the Mechanism of Aldehyde Oxidase and Xanthine Oxidase.” J Org Chem. 73 (23): 9469-9472.

Alfaro, J.F., Joswig-Jones, C. A., Ouyang, W., Nichols, J., Crouch, G.J., Jones, J.P. (2009). “Purification and Mechanism of Human Aldehyde Oxidase (Aox1) Expressed in E. Coli” Drug Metab Dispos, accepted for publication.

Peng, C.C., Pearson J. T., Rock, D.A., Joswig-Jones, C.A., Jones, J.P. (2010). “The Effects of Type ll Binding in Metabolic Stablility and Binding Affinity in Cytochrome P450 CYP3A4.” Arch Biochem Biophys. 497:68-81. PMC2864005.

Roberts, K.M., Jones, J.P. “Anilinic N-Oxides Support Cytochrome P450-Mediated N-Dealkylation trhough Hydrogen-Atom Transfer” (2010) Chem. Eur, J. 16, 8096-8107

Barr, John, and Jeffrey Jones. “Inhibition of Human Liver Aldehyde Oxidase: Implications for Potential Drug-Drug Interactions.” Drug Metab Dispos: the biological fate of chemicals (2011) doi:10.1124/dmd.111.041806.

Dahal, Upendra P, Jeffrey P Jones, John A Davis, and Dan A Rock. “Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates.” Drug Metab Dispos 39, no. 12 (2011): doi:10.1124/dmd.111.040865.

Jones, Jeffrey P, Carolyn A Joswig-Jones, Michelle Hebner, Yuzhuo Chu, and Dennis R Koop. “The Effects of Nitrogen-Heme-Iron Coordination on Substrate Affinities for Cytochrome P450 2E1.” Chemico-Biological Interactions 193, no. 1 (2011): doi:10.1016/j.cbi.2011.05.001.

Pearson, Joshua, Upendra P Dahal, Daniel Rock, Chi-Chi Peng, James O Schenk, Carolyn Joswig-Jones, and Jeffrey P Jones. “The Kinetic Mechanism for Cytochrome P450 Metabolism of Type II Binding Compounds: Evidence Supporting Direct Reduction.” Arch Biochem Biophys 511, no. 1-2 (2011): doi:10.1016/j.abb.2011.04.008.

Locuson CW, Alfaro JF, Zaya MJ, Billen D, White JA, Jones JP. “A non-acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21.” Drug Metab Lett. 5(4):253-8, (2011)

Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP. Leimkühler S. “The impact of single nucleotide polymorphisms on human aldehyde oxidase.” Drug Metab Dispos. 40(5):856-64, (2012): dmd 40:1-9.

Barr, J. T., and Jones, J. P. (2012) Evidence for Substrate Dependent Inhibition Profiles for Human Liver Aldehyde Oxidase, Drug Metab Dispos . 41:1-6.

Dahal, U. P., Joswig-Jones, C., and Jones, J. P. (2012) Comparative study of the affinity and metabolism of type I and type II binding quinoline carboxamide analogues by cytochrome P450 3A4, J Med Chem 55, 280-290.

Poudel, K.R., Jones, J.P., and Brozik, J.A. “A Guide to Tracking Single Transmembrane Proteins in Supported Lipid Bilayers” Methods in Molecular Biology, Chapter 11, Springer Press, Vol. 974, Editor: Jorg Kleinschmidt, ISBN: 978-1-62703-274-2, Release February 28, 2013

Jones, J.P. and Korzekwa, K.R. (2013) Predicting Intrinsic Clearance for Drugs and Drug Candidates Metabolized by Aldehyde Oxidase, Mol. Pharmaceutics, Article ASAP DOI: 10.1021/mp300568r

Barr, J. T., and Jones, J. P. (2013) “Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase”, Drug Metab Dispos 41, 24-29.

Choughule, K. V., Barr, J. T., and Jones, J. P. (2013) “Evaluation of rhesus monkey and Guinea pig hepatic cytosol fractions as models for human aldehyde oxidase”, Drug Metab Dispos 41: 1852-1858.

Sanchez, E. J., Hayes, R. P., Barr, J. T., Lewis, K. M., Webb, B. N., Subramanian, A. K., Nissen, M. S., Jones, J. P., Shelden, E. A., Sorg, B. A., Fill, M., Schenk, J. O., and Kang, C. (2013) Potential role of cardiac calsequestrin in the lethal arrhythmic effects of cocaine, Drug and Alcohol Dependence ASAP.

JT Barr, JP Jones, CA Joswig-Jones, DA Rock (2013) Absolute Quantification of Aldehyde Oxidase Protein in Human Liver Using Liquid Chromatography–Tandem Mass Spectrometry, Molecular Pharmaceutics 2013 10 (10), 3842-3849.

Weidert,E.R., Schoenborn,S.O., Cantu-Medellin,N., Choughule,K.V., Jones,J.P., Kelley,E.E. (2014) Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: Implications for identifying molybdopterin nitrite reductases, Nitric Oxide, 37:41–45.

Barr,J.T., Choughule,K., Nepal,S., Wong, T., Chaudhry,A.S., Joswig-Jones,C.A., Zientek, M.A., Strom, S., Schuetz,E.G., Thummel,K., Jones,J.P. (2014) Why Do Most Human Liver Cytosol Preparations Lack Xanthine Oxidase Activity? Drug Metab Dispos 113.056374

Barr, J. T., Choughule, K. V., Jones, J. P (2014) “ Enzyme Kinetics, Inhibition, and Regioselectivity of Aldehyde Oxidase” Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications, Chapter 9, Humana Press, Methods Mol Biol. Vol. 1113, ISBN: 978-1-62703-757-0

Choughule, K. V., Barnaba, C., Joswig-Jones, C. A., and Jones, J. P. (2014) In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase, Drug Metab Dispos 42, 1334-1340.

Green, A. R., Lewis, K. M., Barr, J. T., Jones, J. P., Lu, F., Ralph, J., Vermerris, W., Sattler, S. E., and Kang, C. (2014) Determination of the Structure and Catalytic Mechanism of Sorghum bicolor Caffeic Acid O-Methyltransferase and the Structural Impact of Three brown midrib12 Mutations, Plant Physiol 165, 1440-1456

Nagar, S., Jones, J. P., and Korzekwa, K. (2014) A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations, Drug Metab Dispos 42, 1575-1586.

Barr, J. T., Jones, J. P., Oberlies, N. H., and Paine, M. F. (2015) Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance, Drug Metab Dispos 43, 34-41.

Sodhi JK, Wong S, Kirkpatrick DS, Liu L2, Khojasteh SC, Hop CE, Barr JT, Jones JP, Halladay JS. (2015) A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 2015 Jun;43(6):908-15.

Choughule KV, Joswig-Jones CA, Jones JP. (2015) Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase. Biochemical pharmacology. 2015; 96(3):288-95.

Barden, A. O., Goler, A. S., Humphreys, S. C., Tabatabaei, S., Lochner, M., Ruepp, M. D., Jack, T., Simonin, J., Thompson, A. J., Jones, J. P., and Brozik, J. A. (2015) Tracking individual membrane proteins and their biochemistry: The power of direct observation, Neuropharmacology 98, 22-30. (Impact Factor 5.1)

Scott, EE, Wolf, CR, Otyepka, M, Humphreys, SC, Reed, JR., Henderson, CJ, McLaughlin, LA, Paloncyova, M, Navratilova, V, Berka, K, Anzenbacher, P, Dahal, UP, Barnaba, C, Brozik, JA, Jones, JP, Estrada, F, Laurence, JS, Park, JW, and Backes, WL. (2016) The Role of Protein-Protein and Protein-Membrane Interactions on P450 Function, Drug Metab Dispos .2016 Feb 5. pii: dmd.115.068569. [Epub ahead of print]

Barnaba, C., Humphreys, S. C., Barden, A. O., Jones, J. P., and Brozik, J. A. (2016) Substrate Dependent Native Luminescence from Cytochromes P450 3A4, 2C9, and P450cam, J Phys Chem B 120, 3038-3047. (Impact Factor 3.3)

Research Projects Ongoing During the Last 3 Years

ACTIVE

“Understanding the Metabolic Impact of Aldehyde Oxidase on New Drug Design”
Principal Investigator: Jeffrey P. Jones
Agency: National Institutes of General Medical Sciences
Type of Award: 9R01 GM100874, 06/01/12-03/31/20
The goal of this study is to develop in silico models for aldehyde oxidase binding affinities, and in vivo clearance.

“Improving Prediction of Drug Interactions Mediated by Time-Dependent Inhibitors”
Principal Investigator: Swati Nagar (Jones WSU PI with Jim Brozik)
Agency: NIH
Type of Award:   RO1  GM114369 ,  01/01/16-/11/30/19

“Consortium for Nature-Inspired Lignocellulosic Biomass Processing”
Principal Investigator: Chen
Agency: NSF
Type of Award: 1231085, 09/01/12-08/31/16

“Drug Interactions and Low-Spin Drugs”
Principal Investigator: William Atkins
Agency: NIH
Type of Award: 04/01/14-03/31/19

COMPLETED

“Development of a Malarial Kinase-on-Phage Screening Platform”
Principal Investigator: Cliff Berkman
Agency: NIH-NIAID
Type of Award: R21AI094315, 08/01/12-07/31/14

“Predicting Rates and Regioselectivity in Cytochrome P450 Mediated Reactions”
Principal Investigator: Jeffrey P. Jones
Agency: National Institutes of General Medical Sciences
Type of Award: 9R01 GM084546, 09/10/08-06/30/12
This is a continuation of the “Cytochrome P450 Models for Risk Assessment” grant.

“Cytochrome P450 Models for Risk Assessment”
Principal Investigator: Jeffrey P. Jones
Agency: National Institutes of Environmental Health
Type of Award: R01 ES09122, 5/1/03-4/31/08
The long term objective of this research proposal is to develop energy relationships for predictive models for the cytochrome P450 enzymes.  The cytochrome P450 enzymes (P450s) are versatile catalysts that play an important role in both the detoxification and bioactivation of chemicals.

“Drug Interactions”
Principal Investigator: (Rettie)
Agency: National Institute of General Medicine
Type of Award: P01 GM32165 8/1/83-7/31/08
To explore drug interactions in P450-catalyzed reactions with a focus on mechanism and clinical aspects.